A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910